- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
U.S. FDA recently conducted an inspection of Apitoria Pharma's API manufacturing facility, resulting in a Voluntary Action Indicated (VAI) classification. During the inspection, the FDA issued Form 483, citing 10 procedural observations related to current Good Manufacturing Practices (cGMP). Fortunately, this action is not expected to impact the financials or operations of Aurobindo Pharma. The company is closely monitoring the situation and addressing the observations noted by the FDA. Positive outlook remains as the facility continues to operate without financial disruption. Stakeholders should watch closely for any developments that could arise from this inspection.